Over the past few decades, research has primarily focused on defining the genomic landscape of primary melanoma and metastatic disease, uncovering key genetic alterations, such as BRAF, NRAS, AKT1, and PTEN mutations, that shed light on melanoma progression and treatment resistance [3,4,[7], [8], [9]]. This evidence concerns the gene BRAF and melanoma.